Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"Netarsudil"”.
-
The effects of netarsudil on Schlemm's canal inner wall endothelial cells
… the IOP slows the progression of glaucoma. Netarsudil, sold under the brand name “Rhopressa,” is a rho-kinase/NE transporter inhibitor that lowers elevated IOP in patients with open-angle glaucoma or ocular hypertension. A previous study showed that netarsudil uses a number of mechanisms to …
-
Advanced Delivery Platforms for Netarsudil: Microneedle-Implant Devices and Suprachoroidal Nanocrystals for Glaucoma Treatment
Netarsudil is an FDA-approved Rho-kinase (ROCK) inhibitor that effectively lowers intraocular pressure (IOP) for glaucoma treatment. However, traditional topical administration of Netarsudil causes frequent instances of conjunctival hyperemia, which severely limits patient adherence and clinical …
-
The effect of netarsudil on pore densities of Schlemm's canal inner wall endothelium in human eyes
BACKGROUND: Netarsudil, a Rho kinase and norepinephrine transport (NET) inhibitor, is a new FDA approved drug used for decreasing raised intraocular pressure (IOP) in ocular hypertensive and primary open-angle glaucoma (POAG) patients. Previous studies reported that netarsudil increased outflow …
-
The effect of netarsudil on the size and types of giant vacuoles in the inner wall endothelium of Schlemm’s canal of perfusion-fixed human eyes using serial block-face scanning electron microscopy
… I-pore(s) are present is called a Type IV GV. Netarsudil, a newly approved topical Rho-kinase (ROCK)/norepinephrine (NET) inhibitor medication for glaucoma, has been shown to increase outflow facility via multiple mechanisms in human eyes. While netarsudil has been shown to increase GVs size, …
-
The effects of a new class of glaucoma treatment drug netarsudil on cellular connections of Schlemm’s canal endothelium
… IOP, by using medicine, laser and surgery. Netarsudil, is one of Rho-Kinase inhibitors, which is a relatively new medication to lower IOP in glaucoma and ocular hypertension. A previous study in Dr. Gong’s lab found that Netarsudil increased outflow facility in human eyes; it induced …
-
Morphological investigation on the effects of netarsudil on the volume of giant vacuoles in Schlemm’s canal endothelial cells of human eyes
… that is currently used to lower IOP in POAG is netarsudil, a Rho kinase/norepinephrine transporter inhibitor. Previous studies conducted in the Gong lab showed that netarsudil increases outflow facility through trabecular meshwork expansion and episcleral vein dilation, leading to an increase in …
-
Repurposing Rho-associated kinase (ROCK) inhibitors for the treatment of Alzheimer’s disease: it’s time to ROCK and Rho
… mouse models. Here we show that ROCK inhibitor netarsudil which is FDA-approved and commercially available in the United States, can penetrate the blood-brain barrier (BBB) and exhibit prolonged retention in the brain relative to the systemic circulation. Additionally, analysis of brain tissue …
-
Drug delivery strategies to overcome ocular hypertension
… Similar to conventional lipid nanoparticles, netarsudil was co-formulated with an siRNA to form IDNPs. By testing a series of formulations, the 45:5 molar ratio of netarsudil to SM-102, a highly potent ionizable lipid, was chosen to encapsulate an siRNA therapeutic based on its balance of drug …
-
Co-delivery of Ionizable Colloid Forming Drugs with Therapeutic Nucleic Acids
… Using the information from these analyses, netarsudil, a glaucoma drug, was predicted to complex and encapsulate siRNA at high efficiency in nanoparticles. Incorporation of a small amount of ionizable lipid increased the potency of siRNA delivery by netarsudil nanoparticles. These …
-
The role of effective filtration area in regulating aqueous outflow facility and intraocular pressure
… designed to increase outflow facility by using netarsudil, a recently approved Rho kinase inhibitor class glaucoma medication, in normal human donor eyes. The second experiment was designed to increase IOP with topical steroid treatment for 5 weeks in mice. The purpose of this study is to verify …
-
Development and Characterization of Cannabidiol and Rho Kinase Inhibitor Combination Formulations for Ophthalmic Use
… FDA approved a 0.02% ophthalmic solution of netarsudil mesylate (NM), Rhopressa®, a rho kinase inhibitor, for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; the first new drug class in more than two decades. Cannabidiol (CBD) has been studied for its …
-
Novel Formulation Strategies for Oral and Ocular Drug Delivery
… formulations latanoprost and Rhopressa® (netarsudil). THC-NEC (0.6 %w/v), THC-VHS-NE (1.0 % w/v), and THC-VHS-NEC (1.0 %w/v), formulations were prepared using hot homogenization followed by probe sonication method and characterized. THC-NEC, THC-VHS-NE, THC-VHS-NEC, latanoprost, and …